wet AMD
Novartis and Bayer seek to oppose High Court ruling over NHS decision to use cheaper drug
October 16, 2018Manufacturing and Production Bayer, CCG, NHS, Novartis, avastin, wet AMD
Swiss multinational Novartis have joined German pharma firm Bayer in appealing a High Court ruling over 12 NHS clinical commissioning …
Regeneron and Ocular Therapeutix to collaborate in potential $315 million deal
October 14, 2016Medical Communications Bayer, Eyelea, Ocular Therapeutix, Regeneron Pharmaceuticals, wet AMD
Regeneron Pharmaceuticals and Ocular Therapeutix have entered into a deal that will see them collaborate to develop a sustained release …
EU nod for Roche cancer drug and chemotherapy
April 8, 2015Sales and Marketing Cancer, Roche, avastin, bevacizumab, cervical, chemotherapy, wet AMD
The European Commission has approved Roche’s Avastin in combination with standard chemotherapy for women with advanced cervical cancer. Avastin (bevacizumab) …
Novartis accused of Lucentis ‘campaign’ against Avastin
April 2, 2015Sales and Marketing Lucentis, NHS, Novartis, avastin, bevacizumab, ranibizumab, wet AMD
Novartis “embarked on a campaign to undermine and divert attention” from a cheap drug for vision loss and maintain the …
Doctors appeal to prescribe Avastin off-label
February 25, 2015Sales and Marketing Lucentis, NHS, NICE, Novartis, Roche, bevacizumab, wet AMD
NHS Clinical Commissioners have called for the removal of barriers preventing CCGs from prescribing Roche’s Avastin to treat wet age-related …
Roche/Novartis offices raided over anti-competitive activities
April 11, 2014Sales and Marketing Lucentis, Novartis, Roche, SHIP Cluster, avastin, wet AMD
French competition authorities are investigating Roche and Novartis in connection with their marketing of Lucentis for wet age-related macular degeneration …
Bayer and Regeneron to co-develop wet AMD antibody
January 14, 2014Research and Development, Sales and Marketing Bayer, Eylea, Regeneron, pdgfr-beta, wet AMD
Bayer and Regeneron are co-developing an antibody to the Platelet Derived Growth Factor Receptor Beta (PDGFR-beta) as a combination therapy …
Eylea receives new European approval
August 30, 2013Research and Development, Sales and Marketing Bayer, CRVO, Eylea, Lucentis, Novartis, wet AMD
Eylea approval for wet AMD
November 29, 2012Sales and Marketing Bayer, Eylea, Lucentis, Novartis, avastin, wet AMD
Bayer HealthCare’s Eylea has been appoved in Europe for the treatment of neovascular age-related macular degeneration (wet AMD). The eye …
New Avastin data could be bad news for Lucentis
August 14, 2012Research and Development, Sales and Marketing DMO, Lucentis, Novartis, Roche, avastin, off label, off-label, wet AMD
The day after Novartis gained a new US licence for Lucentis to treat diabetic macular oedema, new data was published …
Lucentis gains new licence in the US
August 13, 2012Sales and Marketing Eylea, FDA, Lucentis, approval, avastin, wet AMD
Roche’s eye drug Lucentis has gained a new licence in the US to treat diabetic macular oedema. The FDA has …
Novartis right to challenge NHS on Avastin use – ABPI chief
April 27, 2012Sales and Marketing ABPI, Lucentis, Whitehead, avastin, wet AMD
The ABPI has declared its support for Novartis in its legal challenge against off-label prescribing in England.The pharma company is …
Charity challenges government on Avastin for wet AMD
April 24, 2012Sales and Marketing Lucentis, Novartis, Roche, avastin, off label, off-label, wet AMD
A leading patient group has called on the government to get to grips with the issue of off-label prescribing, as …
Bayer eye drug succeeds in long-term study
February 21, 2012Research and Development, Sales and Marketing Bayer, Lucentis, aflibercept, wet AMD
Bayer’s eye drug aflibercept has succeeded in a long-term study in patients with a common eye condition. The Phase III …
Latest content
